The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exposure–efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC).
Bei Wang
Employment or Leadership Position - Genentech
Jin Jin
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Other Remuneration - Genentech
Russell Wada
No relevant relationships to disclose
Liang Fang
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Dan Lu
Employment or Leadership Position - Genentech
Stock Ownership - Genentech/Roche
Ellie Guardino
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Sandra M. Swain
Consultant or Advisory Role - Genentech/Roche
Research Funding - BiPar Sciences/Sanofi; Bristol-Myers Squibb; Genentech/Roche; Puma Biotechnology; Roche; Sanofi
Michael Untch
No relevant relationships to disclose
Sandhya Girish
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Research Funding - Genentech